NCT01690871 2013-08-02A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaNovartisPhase 2 Withdrawn
NCT01290406 2012-06-21BEZ235 Trial in Patients With Advanced Endometrial CarcinomaNovartisPhase 2 Withdrawn
NCT01288092 2012-06-07BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast CancerNovartisPhase 2 Withdrawn